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Strain differences rather than hyperglycemia determine the se-
verity of glomerulosclerosis in mice.
Background. We reported that ROP, but not C57, mice were
prone to glomerulosclerosis (GS) after nephron reduction (J Clin
Invest 97:1242, 1996).
Methods. In this study, we induced diabetes in ROP and C57
mice to determine if the glomerulosclerotic response was stimulus
specific. We used the oligosyndactyly mutation (Os), to produce a
congenital 50% reduction in nephron number. Stable hyperglyce-
mia was induced by streptozotocin and mice were maintained for
12 weeks without insulin treatment.
Results. Glomerular hypertrophy occurred in diabetic ROP
1/1 and C57 1/1 mice, but glomeruli of diabetic ROP 1/1 mice
had 1.92-fold higher laminin B1 and 1.5-fold higher tenascin
mRNA levels than diabetic C57 1/1 mice. Diabetic ROP Os/1
mice had severe glomerulosclerosis with arteriolar and tubuloin-
terstitial lesions while there was only moderate mesangial sclerosis
in diabetic C57 Os/1 mice. Glomerular size was increased in all
non-diabetic Os/1 mice. It was further increased in diabetic ROP
Os/1 mice, but not in diabetic C57 Os/1 mice. Glomerular
mRNA levels were higher in diabetic ROP OS/1 than in diabetic
C57 OS/1 mice [a1 (IV) collagen 3.2-fold, laminin B1 2.1-fold,
and tenascin 1.6-fold].
Conclusion. Overall, our data further support the hypothesis
that the susceptibility to glomerulosclerosis is inherited, and
suggest that hyperglycemia serves principally as a triggering event
in the development of diabetic nephropathy. Since the accelera-
tion of diabetic nephropathy by nephron reduction was also
largely strain dependent, it appears that the propensity to glomer-
ulosclerosis is a general renal response and is not stimulus specific.
Diabetic nephropathy is one of the major causes of
morbidity and mortality among diabetics [1–3]. Hypergly-
cemia, early and advanced glycosylation end-products
(AGEs), and elevated growth hormone levels (GH) have
been implicated in the glomerular lesions of diabetic
nephropathy [4, 5]. However, not all patients with these
abnormalities develop glomerular lesions, and the severity
and rate of progression of the nephropathy varies widely.
Epidemiological studies reveal that there is family cluster-
ing of diabetic nephropathy and that ethnicity plays an
important role in the risk of its development and progres-
sion [6–8]. The genesis of lesions in vascular beds other
than the kidney, such as the eye, appears to be more closely
related to the underlying metabolic abnormalities [6, 7].
The genetic make-up underlying the propensity to dia-
betic nephropathy has not been characterized. Further, it is
not known whether the propensity to develop glomerulo-
sclerosis is specific to the individual stimulus or represents
a general response. One predisposing factor could be an
inborn deficit in nephron number. The glomerular lesions
due to this deficit may only become manifest in later life
[9–11]. There is increasing evidence that the number of
glomeruli at birth can be influenced by multiple factors,
including placental weight, birth weight, and exposure to
toxins in utero [12, 13]. Low birth weight is linked to an
increased risk of hypertension, end-stage renal disease [12],
and diabetic nephropathy [10]. While these data suggest
that glomerulosclerosis is a general response, it has not
been directly assessed.
A radiation induced mutation resulted in oligosyndactyly
(Os) and a congenital reduction in the number of nephron
[14]. Using mice carrying the Os mutation, we found that
genetic susceptibility to glomerulosclerosis was indepen-
dent of reduction in nephron number, and that a deficit in
nephron number induced sclerosis only in susceptible
strains [14]. In the current study, we tested the hypothesis
that the severity of diabetic nephropathy is influenced by
the genetic background and that hyperglycemia served
principally as a triggering event. We found that the predis-
position to the development of diabetic glomerulosclerosis
depends largely on the mouse strain. The inborn reduction
in nephron number served as a stimulus to promote the
development of diabetic glomerulosclerosis in sclerosis-
prone mice, but not in sclerosis-resistant mice.
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METHODS
Experimental design
Female C57 1/1, ROP 1/1, C57 Os/1, and ROP Os/1
mice were obtained from Jackson Laboratories (Bar Har-
bor, ME, USA) and diabetes was induced at 12 weeks of
age using streptozocin (STZ). Seven to fourteen intraperi-
toneal injections of 50 mg/g body wt of STZ, or vehicle
solution (citrate buffer) were administered within two
weeks [5]. Mice were weighed and blood glucose levels
were determined at baseline and weekly thereafter. Only
mice that reached stable hyperglycemia between 240 to 400
mg/dl were included in the study. After a 12 weeks fol-
low-up without insulin treatment, groups of six mice were
sacrificed according to National Institutes of Health ap-
proved procedures. The left kidney was perfused with a
buffer solution containing collagenase and RNAse inhibi-
tors for glomerular microdissection as described previously
[15]. The right kidney was used for microscopic studies.
Light microscopy
Coronal kidney sections were fixed in Carnoy’s fixative,
embedded in glycol methacrylate, cut at a thickness of 2
mm, and stained with periodic acid-Schiff. The sections
were examined without knowledge of the experimental
groups. The degree of glomerulosclerosis was assessed
using a scale from 0 to 41. Forty glomeruli per section were
examined and the mean of scores for individual glomeruli
was recorded [16, 17].
Morphometry
Morphometric analysis was performed on plastic-embed-
ded sections using a digitizing tablet and a video camera.
The mean glomerular volume was derived from the har-
monic mean of the glomerular equatorial surface area [18].
Glomerular cell number and turnover
The nuclei of 40 to 50 successively encountered glomer-
ular profiles were counted and the mean of glomerular cell
number was calculated.
After 3H thymidine administration, nuclei that contained
.5 grains in 40 to 50 successive glomeruli were counted in
each section. The labeling index was calculated as the
number of labeled cells (excluding Bowman’s capsular
cells) divided by the total glomerular cell number 3100
[18].
Isolation of glomeruli, reverse transcription in situ, and
competitive PCR
Glomeruli were isolated by microdissection and glomer-
ular cDNA was obtained by in situ reverse transcription
[15]. The primers for mouse a1 (IV) collagen, laminin B1,
tenascin, and b-actin were previously described [19]. The
corresponding polymerase chain reaction (PCR) products
were 484 bp for a1 type (IV) collagen, 443 bp for laminin
B1, 548 bp for tenascin, and 460 bp for b-actin.
Competitive PCR assays were performed by adding
decreasing amounts of mutant templates to glomerular
cDNA. After PCR amplification, the ratio of mutant to
glomerular cDNA band density was calculated by laser
densitometry and plotted as a function of the amount of
initial mutant template added to the reaction [15]. The
amount of glomerular cDNA was derived from linear
regression analysis and expressed as mRNA levels. Dupli-
cate assays were performed. A representative competitive
PCR assay is shown in Figure 1. Glomerular a1 type (IV)
collagen, laminin B1 and tenascin mRNAs levels were
corrected for b-actin mRNA levels and expressed as ratios.
Statistical analysis
All values were expressed as mean 6 SD. The two-tailed
unpaired Student’s test was used to evaluate differences
between means for corresponding sets of data obtained
from the diabetic and control mice. The level of signifi-
cance (P , 0.05) was chosen a priori for all the analyses
performed in the present study. The two-tailed unpaired
Mann-Whitney nonparametric test was used to analyze
differences in mRNA levels and sclerosis score between
strains.
RESULTS
Body weight, heart weight and blood glucose levels
There were no significant differences in body or heart
weight between diabetic C57 1/1, ROP 1/1, C57 Os/1,
ROP Os/1, and non-diabetic controls (Table 1). Blood
glucose remained at the same levels in all groups of diabetic
mice during the three months follow-up, and none received
insulin.
Glomerular volume
Diabetic ROP 1/1 and C57 1/1 mice had a significant
increase in glomerular volume (Fig. 2A), but the increment
was higher in the diabetic ROP 1/1 mice. As previously
described, glomerular volume was significantly increased in
C57 Os/1 and ROP Os/1 mice as compared to their
respective controls (Table 1) [14].
Glomerular volume was further increased in ROP Os/1
mice after the induction of diabetes, while there was no
increase in glomerular volume in diabetic C57 Os/1 mice
(Fig. 2B).
Glomerular cell number and turnover
No significant increase in glomerular cell number or
labeling index was found in the four groups of diabetic mice
compared to their respective controls. We previously found
that both mean glomerular cell number and labeling index
were increased significantly in C57 Os/1 and ROP Os/1
mice, compared to non-Os controls [14].
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Histology
There were no glomerular lesions by light microscopy in
control C57 1/1 and ROP 1/1 mice (Fig. 3A and 3C).
Diabetic C57 1/1 mice exhibited a minimal, but diffuse,
increase in PAS positive material in the mesangial areas
without any increase in peripheral basement membrane
thickness (Fig. 3B). The increase in mesangial matrix was
more pronounced in ROP 1/1 than in C57 1/1 diabetic
mice and was not associated with an increase in the number
of nuclei (Fig. 3D). This was further documented using a
semiquantitative scoring method that showed that the
mean mesangial sclerosis was 1.33 6 0.26 in diabetic ROP
1/1 mice compared to 0.83 6 0.26 in diabetic C57 1/1
mice (P , 0.05). As described previously [14], glomerular
cell number was increased in both C57 Os/1 and ROP
Os/1 mice and C57 Os/1 mice had minimal glomerular
lesions, while ROP Os/1 mice had moderate to severe and
diffuse glomerulosclerosis consisting of an increase in
mesangial matrix but not in peripheral basement mem-
brane thickness. No area of segmental sclerosis with syn-
echiae was observed. Most Bowman’s capsules appeared
normal or minimally thickened (Fig. 4 A, C). Diabetic C57
Os/1 mice had moderate mesangial sclerosis that did not
affect all spaces and was not associated with any aneurys-
mal dilation of peripheral loops. The interstitial compart-
ment did not show any lesions. Tubular basement mem-
brane were not thickened. Arteries and arterioles were
normal (Fig. 4B). In contrast, all diabetic ROP Os/1 mice
had diffuse and severe glomerulosclerosis with Kimmel-
stiel-Wilson nodules. All mesangial spaces were markedly
enlarged. Occasional aneurysmal dilations of the vascular
loops were also present. In many glomeruli there was a
significant decrease in the vascular lumina. Large synechiae
were present. Occasional obsolescent glomeruli were
found. Bowman’s capsules were massively thickened. The
interstitial tissue was markedly increased and contained
areas of cellular infiltration. The majority of tubules exhib-
ited severe tubular basement thickening. There were arte-
riolar lesions consisting in subintimal deposits. (Fig. 4D).
Accordingly, the mean mesangial sclerosis score was 2.83 6
Fig. 1. Representative experiments for competitive polymerase chain reaction (PCR) for glomerular b-actin, laminin B1, a1 (IV) collagen and
tenascin. Competitive PCR was performed as described. cDNA from 1/10th glomerulus (wild-type) competed with decreasing amount of mutant cDNA.
In these experiments, the mutant range was 0.02-0.001 amol (lane 1 to 6) for b-actin, 0.004-0.0001 amol (lanes 1 to 6) for laminin B1, 0.04-0.0002 amol
(lanes 1 to 8) for a1 (IV) collagen, and 0.01-0.002 amol (lanes 1 to 6) for tenascin. Glomerular cDNAs were measured at least in duplicate. PCR products
were separated on 4% agarose gel.
Table 1. Comparison of body weight, heart weight, heart weight/body weight ratio, and blood glucose levels
Strain: C57 1/1 ROP 1/1 C57 Os/1 ROP Os/1
Group: Control Diabetic Control Diabetic Control Diabetic Control Diabetic
Body weight g 21.3 6 0.9 20.78 6 0.77 21.88 6 1.07 21.5 6 1.41 24.32 6 1.67 21.93 6 1.36 23.42 6 2.36 19.32 6 2.21
Heart wt mg 112 6 14 107.33 6 4.52 90.63 6 3.26 105.71 6 18 109.9 6 7.46 126.13 6 26.45 120.42 6 13.57 94.28 6 18.91
Heart wt/body wt 0.005 6 0.0001 0.005 6 0.001 0.004 6 0.0003 0.005 6 0.001 0.005 6 0.0001 0.006 6 0.001 0.005 6 0.001 0.005 6 0.001
Blood glucose mg/dl 86.67 6 20.66 340 6 59.28 78.33 6 13.29 314 6 66 87.5 6 11.72 333 6 32.66 78.33 6 13.29 340 6 54
There were six mice in each group.
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0.4 in the diabetic C57 Os/1 mice and 3.75 6 0.27 in
diabetic ROP Os/1 mice (P , 0.01).
mRNA levels
The values of a1(IV) collagen, laminin B1 and tenascin
obtained by competitive PCR were normalized to b-actin
(Fig. 5). There was a comparable increase in glomerular
a1(IV) collagen mRNA levels in diabetic C57 1/1 and
ROP 1/1 mice, compared to controls (Fig. 5A). As
reported previously, glomerular a1(IV) collagen mRNA
levels were higher in ROP Os/1 mice than in C57 Os/1
mice. Diabetic ROP OS/1 but not C57Os/1 mice, had
increased a1(IV) collagen mRNA levels, compared to
non-diabetic controls (Fig. 5 B).
Glomerular laminin B1 mRNA levels were increased in
both diabetic C57 1/1 and ROP 1/1 mice, compared to
controls (Fig. 5C). However diabetic ROP 1/1 mice had
1.92-fold higher laminin B1 mRNA levels than diabetic C57
1/1 mice (P , 0.05). Furthermore, diabetic ROP Os/1
had significantly increased laminin B1 mRNA levels, com-
pared to non-diabetic controls (Fig. 5 D), while there were
no significant differences between diabetic and non-dia-
betic C57 Os/1 mice.
Glomerular tenascin mRNA levels were increased in
diabetic C57 1/1 and ROP 1/1 mice, compared to
controls (Fig. 5E). However, diabetic ROP 1/1 mice had
1.5-fold higher tenascin mRNA levels than diabetic C57
1/1 mice (P , 0.01). Diabetic ROP Os/1 but not C57
Os/1 mice had significantly increased tenascin mRNA
levels (Fig. 5F) compared to non-diabetic Os/1 mice.
DISCUSSION
Multiple data suggest the existence of a genetic propen-
sity for renal lesions in patients with diabetes mellitus. For
instance, it is well established that only a fraction of IDDM
and NIDDM patients develop diabetic nephropathy [6, 7].
Pima Indians and African Americans with diabetes have a
much higher risk of development of diabetic nephropathy
than Caucasians [8]. In family studies Seaquist et al found
that the incidence of nephropathy was 83% in siblings of
Fig. 2. Glomerular volume in diabetic and non-diabetic mice. (A) Glomerular volume in C57 1/1 and ROP 1/1 mice. **P , 0.01, diabetic ROP 1/1
and C57 1/1, compared to non-diabetic controls. (B) Glomerular volume in C57 Os/1 and ROP Os/1 mice. *P , 0.01, diabetic ROP Os/1 mice,
compared to non-diabetic controls.
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Fig. 3. Light microscopy. Periodic acid-Schiff methenamine-stained plastic embedded sections, 3400. (A) C57 1/1, (B) C57 1/1 diabetic, (C) ROP
1/1, and (D) ROP 1/1 diabetic.
Fig. 4. Light microscopy. Periodic acid-Schiff methenamine-stained plastic embedded sections, 3400. (A) C57 Os/1, (B) C57 Os/1 diabetic, (C) ROP
Os/1, and (D) ROP Os/1 diabetic.
probands with diabetic nephropathy but only 17% in sib-
lings of probands without diabetic nephropathy [20]. These
observations suggest that the predisposition to diabetic
nephropathy is hereditary. Although several models have
been proposed on the basis of human studies, the exact
contribution of genetic factors to the pathogenesis of
diabetic glomerulosclerosis is not clear [21, 22].
The experimental models in this study allows the assess-
ment of the relative contributions of genetic factors and
hyperglycemia in the development of diabetic glomerulo-
sclerosis. We compared the glomerular responses to hyper-
glycemia in sclerosis-resistant (C57 1/1) and sclerosis-
prone (ROP 1/1) mice after three months of stable
STZ-induced hyperglycemia. Although C57 1/1 and ROP
1/1 mice had identical glycemic levels, the renal lesions
were more severe in ROP 1/1 than in C57 1/1 mice. To
determine whether the renal lesions were stimulus specific,
we studied animals with a congenital deficit in nephron
number. This stimulus was chosen since it has been shown
that an inborn nephron deficit is a risk factor for the
development of progressive renal disease [10, 22]. The
model chosen was the oligosyndactyly defect, a radiation
induced mutation localized on mouse chromosome 8 that
results in an inborn deficit in nephron number. Although
ROP 1/1 and C57 1/1 mice both have a 50% decrease of
nephron number when they carry the Os gene, we reported
that ROP Os/1 mice developed severe spontaneous glo-
merulosclerosis while C57 Os/1 mice had only minimal
glomerular lesions [14]. The mice were maintained with
similar level of hyperglycemia for three months without
insulin treatment. At sacrifice the renal lesions appeared
quite severe in the diabetic ROP Os/1, contrasting with a
moderate increase in mesangial sclerosis in the C57 Os/1
mice. Thus, the influence of nephron number on the
severity of diabetic glomerulosclerosis appeared to be
strain dependent. These data are consistent with that
obtained in BB rats, which have been shown to be resistant
to glomerulosclerosis after 5/6 nephrectomy [23]. Feld et al
also reported that diabetic BB rats developed only minimal
glomerular lesions including a slight increase in mesangial
volume and in basement membrane thickness despite se-
vere, prolonged hyperglycemia [24]. These results further
support the role of an inherited susceptibility for the
development of glomerulosclerosis. However, in their
study, sclerosis-susceptible rats were not examined.
Other studies in rats have suggested a genetic basis for
Fig. 5. Glomerular mRNA levels in C57 1/1,
ROP 1/1, C57 Os/1, and ROP Os/1 mice
corrected for b-actin. (A and B) a1 (IV)
mRNA levels. *P , 0.05, diabetic C57 1/1 and
ROP 1/1 mice compared to controls. C57 Os/
1 and ROP Os/1 mice. *P , 0.05, diabetic
ROP Os/1 compared to ROP Os/1 controls.
#P , 0.01, diabetic ROP Os/1 compared to
diabetic C57 Os/1 mice. (C and D) Laminin
mRNA levels. **P , 0.05, diabetic C57 1/1
and ROP 1/1 mice compared to controls.
#P , 0.01, diabetic ROP 1/1 mice compared
to diabetic C57 1/1 mice. *P , 0.05, diabetic
ROP Os/1 compared to control ROP Os/1.
&P , 0.01, diabetic ROP Os/1 mice compared
to diabetic C57 Os/1. (E and F) Tenascin
mRNA levels. **P , 0.01, diabetic C57 1/1
and ROP 1/1 mice compared to non-diabetic
controls. #P , 0.01, diabetic ROP 1/1 mice
compared to diabetic C57 1/1 mice. *P ,
0.05, diabetic ROP Os/1 compared to non-
diabetic ROP Os/1 controls. &P , 0.01,
diabetic ROP Os/1 mice compared to diabetic
C57 Os/1 mice.
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both the development and resistance to glomerulosclerosis
[25–27]. Brandis et al described an age-dependent glomer-
ulosclerosis in the Milan normotensive strain (MNS), al-
though rats remain normotensive, while no glomerular
lesions were found in the Milan hypertensive strains (MHS)
rats, despite the presence of hypertension [28].
The component(s) of genetic susceptibility to sclerosis
have been recently examined. In an elegant study utilizing
Fawn-hooded rats, Brown et al have identified two loci
located on chromosome 1 linked to the development of
renal impairment irrespective of hypertension [29]. Genes
involved in IDDM etiology, glucose metabolism, as well as
blood pressure regulation, such as the insertion/deletion
polymorphism of angiotensin-converting enzyme and the
molecular variant of angiotensinogen have also been inves-
tigated [21, 30]. Our previous data demonstrated that the
expression of a1 type (IV) collagen, laminin B1 and
tenascin was selectively up-regulated in several models of
glomerulosclerosis [31]. Since the thickening of the glomer-
ular basal membrane and the accumulation of mesangial
matrix are hallmarks of glomerular lesions in diabetic
nephropathy [3], we investigated the differences in the
glomerular extracellular matrix responses to diabetes by
studying the expression of a1 type (IV) collagen, laminin
B1 and tenascin in microdissected glomeruli. We found
that the mRNA levels of laminin B1 and tenascin were
more elevated in diabetic ROP 1/1 than in diabetic C57
1/1. Similarly, extracellular matrix (ECM) mRNAs were
increased in diabetic ROP Os/1 but not in C57 Os/1 mice.
Previously we had found that hyperglycemia increased
glomerular expression of a1(IV) and laminin B1 mRNAs in
C57/SJL mice [5]. Fukui et al reported that when rats with
STZ-induced diabetes were treated with sufficient insulin
to maintain blood glucose close to normal, the overexpres-
sion of glomerular a1 type (IV) collagen and laminin B1
was reduced [32]. These data suggested that hyperglycemia
per se stimulated the glomerular expression of a1(IV)
collagen and laminin. However, there are results that do
not agree with this conclusion. For instance, in diabetic
NOD mice, glomerular laminin B1 and tenascin, but not
type (IV) collagen mRNAs were found to be increased [19].
In KKAy mice, mRNA cortical levels for type (IV) collagen
were significantly increased, while laminin B1 mRNA levels
remained unchanged [33]. These diverse data may reflect
differences between cortex and isolated glomeruli, mice
strains, the type of diabetic model, the level of hyperglyce-
mia, as well as insulin treatment. In the present work, the
significant differences in laminin B1 and tenascin mRNA
levels between diabetic C57 1/1 and ROP 1/1 mice, and
between diabetic C57 Os/1 and ROP Os/1 mice seem to
indicate that genetic factors may be involved in the regu-
lation of extracellular matrix gene expression. The cause
for the different response to hyperglycemia of glomerular
type (IV) collagen, laminin B1 and tenascin mRNA expres-
sion in C57 1/1 and C57 Os/1 mice is not clear.
Another component of the glomerular response to hy-
perglycemia is glomerular hypertrophy. There is consider-
able experimental evidence that increased glomerular size
is a marker of a propensity to develop glomerulosclerosis
[34], and there are also data suggesting that a similar
relationship exists in humans [35]. In this study, we found
that the correlation between glomerular hypertrophy and
the severity of diabetic glomerulosclerosis depended on
mouse strain. Diabetic ROP 1/1 mice developed more
severe lesions than C57 1/1 mice, though their glomerular
sizes were equal. Interestingly, glomerular size and lesions
were both markedly accentuated in diabetic ROP Os/1
mice, whereas the glomerular size was not changed in
diabetic C57 Os/1 mice and the lesions were much less
severe. These results suggest that in sclerosis-prone strains
glomerular hypertrophy may be unregulated. In contrast,
glomerular size reaches a plateau in sclerosis-resistant
strains, and additional stimuli do not result in further
hypertrophy.
The role of an increased cell number in the glomerular
hypertrophy was also investigated. There was no change in
total glomerular cell number, but there was a small increase
in the labeling index in all diabetic mice. This data suggest
the possibility of apoptosis in diabetic glomeruli, but we
were unable to detect a difference in glomerular apoptotic
Table 2. Glomerular cell turnover, glomerular volume, and glomerular sclerosis score
Strain: C57 1/1 ROP 1/1 C57 Os/1 ROP Os/1
Group: Control Diabetic Control Diabetic Control Diabetic Control Diabetic
GC 31.48 6 1.24 30.77 6 2.64 33.91 6 4.25 33.83 6 2.04 36.93 6 3.51a 36.47 6 1.63 39.09 6 1.52 39.47 6 5.23b
LI % 0.101 6 0.06 0.23 6 0.21 0.11 6 0.06 0.17 6 0.15 0.32 6 0.1a 0.43 6 0.16 0.31 6 0.14a 0.46 6 0.35
GV 106 mm3 0.29 6 0.04 0.39 6 0.06c 0.45 6 0.09 0.62 6 0.08c 0.78 6 0.11 0.94 6 0.16 1.04 6 0.12 1.36 6 0.21c,f
SS 0 0.83 6 0.26d 0 1.33 6 0.26d,e 1.2 6 0.27 2.01 6 0.66d 2.3 6 0.27 3.75 6 0.27d,f
There were six mice in each group. Abbreviations are: GC, glomerular cell number; LI, labeling index; GV, glomerular volume; and SS, sclerosis score.
a P , 0.05,
b P , 0.01, when C57/OS1 and ROP/OS1 mice were compared to C57 1/1 and ROP 1/1 mice, respectively.
c P , 0.05
d P , 0.01, diabetic C57 1/1, ROP 1/1, C57/OS1, and ROP OS/1 mice were compared to their respective non diabetic controls.
e P , 0.01, diabetic ROP 1/1 mice compared to diabetic C57 1/1 mice
f P , 0.01, diabetic ROP OS/1 mice compared to diabetic C57 OS/1 mice
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cells between diabetic and controls mice by immunostain-
ing (data not shown). Young et al found an early increase
in mesangial cell turnover after the onset of STZ-induced
diabetes in rats, but the total glomerular cell number did
not increase significantly [36].
It should be noted that sclerosis-resistant mice respond
to both nephron reduction and hyperglycemia, but that the
responses appear to be self-limited. In contrast, the re-
sponse to these stimuli in sclerosis-prone strains appears to
be progressive. This may be representative of the case in
the spectrum in diabetic patients, where many have an
elevated albumin excretion rate, but a limited number
develop end-stage renal disease.
Overall, our data support the hypothesis that hypergly-
cemia is a necessary, but not sufficient stimulus for the
development of diabetic glomerulosclerosis. In combina-
tion with our previous data, it appears that susceptibility to
glomerulosclerosis is not stimulus-specific, in that both
diabetes mellitus and nephron reduction may serve as
initiators of sclerosis in a susceptible mouse strain. Finally,
the resistance to glomerulosclerosis is also independent of
the stimuli, since both diabetes mellitus and nephron
reduction resulted in much less severe lesions in a sclerosis-
resistant mouse strain.
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